secwatch.observer — SEC 8-K summary
======================================

Issuer:     Atreca, Inc. (—)
CIK:        0001532346
Form:       8-K
Filed at:   2023-08-10T23:59:59+00:00
Accession:  0001171843-23-005224
Event type: other_material
Sentiment:  negative
Materiality: 0.80
Item codes: 2.02, 2.05, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Atreca suspends lead candidate ATRC-101, cuts 40% of staff; Q2 net loss $19.2M
------------------------------------------------------------------------------

- Suspension of ATRC-101 development and ~40% workforce reduction; estimated restructuring costs of $1.6M in Q3 2023.
- Q2 2023 net loss of $19.2M ($0.49 per share); cash and investments totaled $38.5M as of June 30, 2023.
- R&D expenses $12.9M and G&A expenses $6.8M for Q2 2023, including stock-based compensation.
- Focus shifts to preclinical ADC APN-497444; expects to nominate clinical candidate in 2023 and IND in late 2024/early 2025.
- Cash runway expected to fund operations through early 2024; company evaluating additional cost-saving initiatives.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1532346/000117184323005224/0001171843-23-005224-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1532346/000117184323005224/f8k_081023.htm
  HTML page:      https://secwatch.observer/filing/0001171843-23-005224

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer